- Home
- NDLS vs AEON Comparison
NDLS vs AEON Comparison
Compare NDLS & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
BUY
Current Price
$6.51
HOLD
Current Price
$1.17
Company Overview
Basic Information| Metric | NDLS | AEON |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 26.8M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | NDLS | AEON |
|---|---|---|
| Price | $6.51 | $1.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | ★ 71.4K | 70.4K |
| Earning Date | 04-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $493,271,000.00 | N/A |
| Revenue This Year | $2.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.47 | $0.38 |
| 52 Week High | $7.09 | $1.45 |
Technical Indicators
Market Signals| Indicator | NDLS | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 83.10 | 54.38 |
| Support Level | $0.62 | $0.69 |
| Resistance Level | $7.09 | $1.42 |
| Average True Range (ATR) | 0.47 | 0.10 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 75.97 | 70.52 |
Price Performance
Historical Comparison NDLS
AEON
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.